These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 34104205)

  • 1. Angiotensin Receptor Blocker and Calcium Channel Blocker Preventing Atrial Fibrillation Recurrence in Patients with Hypertension and Atrial Fibrillation: A Meta-analysis.
    Ma H; Jiang H; Feng J; Gan Y
    Cardiovasc Ther; 2021; 2021():6628469. PubMed ID: 34104205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study).
    Yamashita T; Inoue H; Okumura K; Kodama I; Aizawa Y; Atarashi H; Ohe T; Ohtsu H; Kato T; Kamakura S; Kumagai K; Kurachi Y; Koretsune Y; Saikawa T; Sakurai M; Sato T; Sugi K; Nakaya H; Hirai M; Hirayama A; Fukatani M; Mitamura H; Yamazaki T; Watanabe E; Ogawa S;
    Europace; 2011 Apr; 13(4):473-9. PubMed ID: 21148662
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of telmisartan on paroxysmal atrial fibrillation recurrence in hypertensive patients with normal or increased left atrial size.
    Fogari R; Zoppi A; Maffioli P; Mugellini A; Preti P; Perrone T; Derosa G
    Clin Cardiol; 2012 Jun; 35(6):359-64. PubMed ID: 22522403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of RAAS Blockers on Atrial Fibrillation Prophylaxis: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Chaugai S; Meng WY; Ali Sepehry A
    J Cardiovasc Pharmacol Ther; 2016 Jul; 21(4):388-404. PubMed ID: 26817632
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-Receptor Blocker, Angiotensin-Converting Enzyme Inhibitor, and Risks of Atrial Fibrillation: A Nationwide Cohort Study.
    Hsieh YC; Hung CY; Li CH; Liao YC; Huang JL; Lin CH; Wu TJ
    Medicine (Baltimore); 2016 May; 95(20):e3721. PubMed ID: 27196491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease.
    Huang RS; Cheng YM; Zeng XX; Kim S; Fu P
    Chin Med J (Engl); 2016 Mar; 129(5):562-9. PubMed ID: 26904991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-amlodipine plus chlorthalidone vs. S-amlodipine plus telmisartan in hypertensive patients unresponsive to amlodipine monotherapy: study protocol for a randomized controlled trial.
    Jo SH; Park SJ; Kim EJ; Kim SJ; Cho HJ; Song JM; Shin J; Park JJ; Shin JH; Han KR; Choi DJ
    Trials; 2018 Jun; 19(1):324. PubMed ID: 29925421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis.
    Cheng Y; Huang R; Kim S; Zhao Y; Li Y; Fu P
    Medicine (Baltimore); 2016 Jul; 95(28):e4167. PubMed ID: 27428210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nifedipine versus telmisartan on prevention of atrial fibrillation recurrence in hypertensive patients.
    Du H; Fan J; Ling Z; Woo K; Su L; Chen S; Liu Z; Lan X; Zhou B; Xu Y; Chen W; Xiao P; Yin Y
    Hypertension; 2013 Apr; 61(4):786-92. PubMed ID: 23438932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.
    Healey JS; Baranchuk A; Crystal E; Morillo CA; Garfinkle M; Yusuf S; Connolly SJ
    J Am Coll Cardiol; 2005 Jun; 45(11):1832-9. PubMed ID: 15936615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between types of antihypertensive medication and the risk of atrial fibrillation: a nationwide population study.
    Choi J; Lee SR; Choi EK; Lee KY; Ahn HJ; Kwon S; Kim B; Han KD; Oh S; Lip GYH
    Front Cardiovasc Med; 2024; 11():1372505. PubMed ID: 38784173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of the efficacy and safety of adding an angiotensin receptor blocker (ARB) to a calcium channel blocker (CCB) following ineffective CCB monotherapy.
    Ma J; Wang XY; Hu ZD; Zhou ZR; Schoenhagen P; Wang H
    J Thorac Dis; 2015 Dec; 7(12):2243-52. PubMed ID: 26793346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study on the Effect of Irbesartan on Atrial Fibrillation Recurrence in Kumamoto: Atrial Fibrillation Suppression Trial (SILK study).
    Yamabe H; Kaikita K; Matsumura T; Iwasa A; Koyama J; Uemura T; Morikami Y; Tsunoda R; Morihisa K; Fujimoto K; Kajiwara I; Matsui K; Tsujita K; Ogawa H
    J Cardiol; 2018 Feb; 71(2):129-134. PubMed ID: 28886992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antihypertensive treatment and risk of atrial fibrillation: a nationwide study.
    Marott SC; Nielsen SF; Benn M; Nordestgaard BG
    Eur Heart J; 2014 May; 35(18):1205-14. PubMed ID: 24347316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ambulatory blood pressure response to triple therapy with an angiotensin-receptor blocker (ARB), calcium-channel blocker (CCB), and HCTZ versus dual therapy with an ARB and HCTZ.
    Duprez D; Ferdinand K; Purkayastha D; Samuel R; Wright R
    Vasc Health Risk Manag; 2011; 7():701-8. PubMed ID: 22174580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination angiotensin-receptor blocker (ARB)/calcium channel blocker with HCTZ vs the maximal recommended dose of an ARB with HCTZ in patients with stage 2 hypertension: the exforge as compared to losartan treatment in stage 2 systolic hypertension (EXALT) study.
    Wright RF; Duprez D; Purkayastha D; Samuel R; Ferdinand KC
    J Clin Hypertens (Greenwich); 2011 Aug; 13(8):588-97. PubMed ID: 21806769
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and Validation of a Medication Selection Model Under Clinical Application of Renin-Angiotensin Inhibitor Combined with Calcium Channel Blocker for Hypertension Patients.
    Hong D; Shi W; Lu X; Lou Y; Li L
    Med Sci Monit; 2020 Apr; 26():e923696. PubMed ID: 32285846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Effect of Renin-Angiotensin System Inhibitors on the Recurrence of Atrial Fibrillation After Catheter Ablation.
    Zhao J; Chen M; Zhuo C; Huang Y; Zheng L; Wang Q
    Int Heart J; 2020 Nov; 61(6):1174-1182. PubMed ID: 33191354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Renin-angiotensin system inhibitors for prevention of recurrent atrial fibrillation: a meta-analysis.
    Li TJ; Zang WD; Chen YL; Geng N; Ma SM; Li XD
    Int J Clin Pract; 2013 Jun; 67(6):536-43. PubMed ID: 23557493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effects of ACEI/ARB, aldosterone receptor antagonists and statins on preventing recurrence of atrial fibrillation: A protocol for systematic review and network meta-analysis.
    Jia Q; Han W; Shi S; Hu Y
    Medicine (Baltimore); 2021 Jan; 100(1):e24280. PubMed ID: 33429839
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.